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Retinoic acid decreases proteinuria and glomerulosclerosis in
several animal models of kidney disease by protecting
podocytes from injury. Our recent in vitro studies suggest
that all-trans retinoic acid induces podocyte differentiation
by activating the retinoic acid receptor-a (RARa)/cAMP/PKA/
CREB pathway. When used in combination with all-trans
retinoic acid, an inhibitor of phosphodiesterase 4 further
enhanced podocyte differentiation by increasing intracellular
cAMP. Additionally, we found that Am580, a specific RARa
agonist, has similar renal protective effects as all-trans
retinoic acid in a rederived colony of HIV-1 transgenic mice
with rapidly progressive renal failure (HIV-Tg) that mimics
human HIV-associated nephropathy. Treatment with either
the inhibitor of phosphodiesterase 4, roflumilast, or Am580
significantly reduced proteinuria, attenuated kidney injury,
and improved podocyte differentiation in these HIV-Tg mice.
Additional renal protective effects were found when
roflumilast was combined with Am580. Consistent with the
in vitro data, glomeruli from HIV-Tg mice treated with both
Am580 and roflumilast had more active phosphorylated
CREB than with either agent alone. Thus, phosphodiesterase
4 inhibitors could be used in combination with RARa agonists
to provide additional renal protection.
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Glomerular kidney disease is a major cause of end-stage renal
disease in the United States.1 Human immunodeficiency
virus (HIV)-associated nephropathy (HIVAN), characterized
as collapsing focal segmental glomerulosclerosis, is a leading
cause of kidney disease in young African Americans.2
Although suppression of viral replication with antiretroviral
therapy alters the course of the kidney disease, many patients
with HIVAN still progress to end-stage renal disease.3
Podocyte injury is a major cause of glomerular disease.
Podocytes undergo apoptosis and detachment in diabetic
kidney disease and classic focal segmental glomerulosclerosis.4,5
Podocyte dedifferentiation and proliferation are considered
as unique features of HIVAN and idiopathic collapsing focal
segmental glomerulosclerosis.6–8 In vitro, HIV infection
causes podocyte proliferation and dedifferentiation.9 Trans-
genic (Tg) mice with expression of HIV-1 in the podocytes
develop kidney disease similar to HIVAN.10 Therefore,
prevention or reversal of podocyte injury is an important
strategy to treat HIVAN as well as other glomerular diseases.
However, no drugs are available to specifically prevent or
reverse podocyte injury.
Retinoids are derivatives of vitamin A and protect against
renal injury in multiple experimental models of kidney
diseases.11 We found that all-trans retinoic acid (ATRA)
reduces proteinuria and glomerulosclerosis in a colony of
HIV-1 Tg mice with rapidly progressive renal failure (HIV-
Tg), which is an animal model of HIVAN.12 An ongoing
phase II clinical trial is examining the effect of ATRA on
patients with glomerular diseases with podocyte injury,
including steroid-resistant minimal change disease, focal
segmental glomerulosclerosis, and HIVAN (http://www2.niddk.
nih.gov/NIDDKLabs/Glomerular_Disease_Primer/). However,
it remains unclear how retinoids improve kidney injury.
Recent studies suggest that ATRA restores the expression of
podocyte differentiation markers, including nephrin, podo-
cin, and synaptopodin, both in vitro and in vivo.13 We found
that ATRA inhibits cell proliferation and restores differentia-
tion markers in HIV-infected podocytes by activating
the cyclic adenosine 30,50 monophosphate (cAMP)/protein
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kinase A (PKA)/cAMP-responsive element binding protein
(CREB) pathway.12,14 These antiproliferative and prodiffer-
entiation effects of RA were further enhanced when used in
conjunction with a phosphodiesterase 4 (PDE4) inhibitor,
which increases intracellular cAMP concentration by block-
ing RA degradation.12 These studies suggest that retinoic acid
(RA) may have additive or synergic effects when given with a
PDE4 inhibitor for protection against podocytes injury and
treatment of glomerular diseases. Consistent with these findings,
it has been shown that ATRA can induce rapid cAMP
production and increase PKA activity in acute myeloblastic
leukemia cells leading to leukemia cell differentiation.9 A
synergistic effect between ATRA and a PDE4 inhibitor has
also been observed for myeloid differentiation.15
We had demonstrated previously that RA increases
intracellular cAMP concentration by activating RA recep-
tor-a (RARa) and treatment of HIV-Tg mice with Am580, a
RARa-specific agonist, induced podocyte differentiation and
attenuated kidney injury in HIV-Tg mice.16 Furthermore,
knockout of RARa aggravated kidney injury in HIV-Tg mice.
On the basis of these findings, we tested the hypothesis that
the combination of a RARa agonist and a PDE4 inhibitor
provides additional renal protection by increasing intracel-
lular cAMP and activating the cAMP/PKA/CREB pathway.
RESULTS
Effects of Am580 and roflumilast on proteinuria and renal
function in HIV-Tg mice
Roflumilast is an oral PDE4 inhibitor recently approved by
the Food and Drug Administration for the treatment of
asthma. As proteinuria in HIV-Tg mice usually develops at
4 weeks of age and peaks at 8–10 weeks, we treated HIV-Tg
mice with vehicle, Am580, roflumilast, or roflumilast with
Am580 starting from 4 weeks of age to 9 weeks of age. No
significant side effects were noted during the treatment. Total
body weight was not significantly different among the four
groups (Figure 1a). The kidney/body weight ratio, which is
known to be increased in HIV-Tg, was significantly reduced
in HIV-Tg mice treated with either roflumilast or Am580
alone or in combination (Figure 1b). Both Am580 and
roflumilast treatments alone prevented the worsening of renal
function significantly and reduced the amount of proteinuria
compared with vehicle treatment (Figure 2). When Am580
and roflumilast were given together, additional reduction in
blood urea nitrogen (BUN) and urinary albumin/creatinine
ratio were observed compare with mice treated with either
Am580 or roflumilast (Figure 2). The percentage of mice that
developed renal failure, which was defined by elevation of
BUN that is more than 2 s.d.s above the mean BUN in the
wild-type (WT) group (BUN430mg/dl) was calculated for
each treatment group (Table 1). All of the vehicle-treated
HIV-Tg mice developed renal failure. Treatment with either
Am580 or roflumilast reduced the percentage of animals with
renal failure to 30% and 40%, respectively. None of the HIV-
Tg mice treated with both drugs developed renal failure
(Table 1). These results indicate that when a RARa agonist
(Am580) is given with a PDE4 inhibitor (roflumilast) there is
an additive effect on renal protection.
Effects of Am580 and/or roflumilast on kidney histology of
HIV-Tg mice
To assess the effects of Am580 and/or roflumilast on kidney
injury, histological analysis was performed on hematoxylin
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Figure 1 | Effects of Am580 and/or roflumilast on body and
kidney weight of HIV-Tg mice. (a) Body weight. Human
immunodeficiency virus (HIV)-transgenic (Tg) mice were treated
with vehicle, Am580, roflumilast (Rof) or RofþAm580 from the
age of 4 weeks (W) to 9 weeks for a total of 5 weeks. The body
weight was recorded weekly. There was no significant difference
among the four groups. (b) Kidney/body weight ratio. At killing,
both body weight and kidney weight were recorded and kidney/
body weight ratio was calculated. There is a significant difference
among the groups (by analysis of variance, Po0.0001). Pair
analysis with Bonferroni correction detected a significant
difference between the HIV-Tgþ vehicle group vs. all other
groups (*Po0.0001, n¼ 10).
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Figure 2 |Proteinuria and BUN. Human immunodeficiency virus
(HIV)-transgenic (Tg) mice were treated with vehicle, Am580,
roflumilast (Rof), or RofþAm580 from the age of 4 weeks (W) to
9 weeks. Serum was used for the determination of blood urea
nitrogen (BUN, a) and urine was measured for albumin and
creatinine to calculate the albumin/creatinine (Cr) ratio (mg/mg)
(b). A significant difference in BUN and albumin/Cr ratio was
detected among the groups by analysis of variance (n¼ 10).
Pairwise comparison with Bonferroni correction revealed
significant difference between HIV-Tgþ vehicle vs. all other
groups (*Po 0.0001); HIV-Tgþ RofþAm580 vs. HIV-Tgþ Rof
(**Po0.001); and HIV-Tgþ RofþAm580 vs. HIV-TgþAm580
(**Po0.001). WT, wild type.
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and eosin-stained kidney sections as described previously.16
We found that Am580 or roflumilast alone attenuated
glomerulosclerosis, podocyte hypertrophy, and tubular cast/
cyst formation. When given in combination, protection
against renal injury in addition to what was observed for each
agent alone was observed (Figure 3a and Table 2). Consistent
with this, a reduction of foot process effacement was also
observed by electron microscopy in HIV-Tg mice treated
with both roflumilast and Am580 (Figure 3b).
Effect of Am580 and/or roflumilast on the expression of
podocyte differentiation markers in HIV-Tg mice
To determine the effects of Am580 and/or roflumilast on
podocyte proliferation and differentiation, we examined the
expression of genes related to podocyte proliferation and
differentiated in isolated glomeruli by real-time polymerase
chain reaction (PCR) analysis as described previously.16
Treatment with either Am580 or roflumilast alone increased
the expression of podocyte-specific markers (WT-1, nephrin,
and synaptopodin; Figure 4a). Combination treatment with
Am580 and roflumilast induced a further increase in
podocyte differentiation marker expression. In contrast,
mRNA levels of cell proliferation markers (cyclin E and
Ki67) were suppressed in glomeruli by treating HIV-Tg mice
with Am580 or roflumilast alone, and a further reduction
in proliferation markers was observed with Am580 and
roflumilast combination treatment (Figure 4b). As a control,
we also examined the mRNA levels of HIV nef gene and
found that treatment of HIV-Tg mice with either Am580 or
roflumilast or both did not affect glomerular nef expression
(Figure 4b). These findings indicate that the beneficial effects
of Rof/Am580 in HIV-Tg mice are likely independent of HIV
viral gene expression. We also confirm the expression of these
markers by immunostaining. The expression of synaptopodin
and nephrin was upregulated in HIV-Tg mice by either
Am580 or roflumilast, and the expression was further
increased in HIV-Tg mice treated with both Am580 and
roflumilast (Figure 5a). In contrast, Ki67 expression was
suppressed in mice treated with roflumilast or Am580 alone
or in combination as compared with mice treated with
vehicle (Figure 5a). By western blot, we also confirmed that
glomerular cyclin E level was suppressed in mice treated with
either Am580 or roflumilast and further suppressed when
treated with both agents (Figure 5b and c). We also noted
that the suppression of Ki67 and cyclin E levels was less
significant with roflumilast compared with Am580. Take
together, these data indicate that combination therapy of
a RARa agonist with a PDE4 inhibitor could provide
protection against podocyte injury in HIV-Tg mice beyond
treatment with a single agent.
Effect of Am580 and/or roflumilast on CREB phosphorylation
The addition of a PDE4 inhibitor to RA enhanced the
differentiation of cultured podocytes by increasing the level
of cAMP production and subsequent activation of the cAMP/
PKA/CREB pathway.12,17 To determine whether the addition
of roflumilast to Am580 also increases the level of cAMP and
activation of the cAMP/PKA/CREB pathway, we examined
glomerular CREB phosphorylation. We found that combina-
tion treatment with Am580 and roflumilast caused an
increase in CREB phosphorylation—as assessed by western
blotting and immunostaining of kidney tissue—more than
treatment with either Am580 or roflumilast (Figure 6).
Colocalization of pCREB and nestin staining was also
observed in mice treated with Am580 or roflumilast alone
or in combination (Figure 6c), indicating that phosphoryla-
tion of CREB is increased in the podocytes. We chose nestin
as a podocyte marker because its expression is preserved in
the kidney of HIV-Tg mice.18,19 These findings are consistent
with our in vitro findings and support that cAMP/PKA/CREB
pathway may have a role in mediating the effects of RA on
podocyte differentiation in vivo.
DISCUSSION
Treatment of kidney glomerular disease is challenging. Many
lines of evidence suggest that RA can improve kidney injury
in animal models of kidney disease.20 Others and we find that
ATRA improves kidney injury likely by protecting podocytes
from injury.12,13 We previously demonstrated that ATRA
restored podocyte differentiation markers in HIV-infected
podocytes by activating the cAMP/PKA/CREB pathway.12
In vitro, we found that the effects of ATRA on podocyte
differentiation were enhanced by the addition of a PDE4
inhibitor, which increased the accumulation of cAMP by
blocking the degradation of cAMP.12 In addition, we
demonstrated that RARa was required for ATRA-induced
cAMP production and the effects of RA on podocyte
differentiation.12 We also found that a RARa agonist
(Am580) reduced protenuria, attenuated kidney injury, and
induced podocyte differentiation in HIV-Tg mice.16 Here, we
further extended our previous findings by studying the renal
protective effect of combining a PDE4 inhibitor (roflumilast)
with a RARa agonist (Am580) in HIV-Tg mice. The
combination of roflumilast and Am580 further reduced
proteinuria, improved renal function and kidney damage,
Table 1 | Effects of Am580 and roflumilast on the
development of renal failure in HIV-Tg mice
No renal
failure
Renal
failure
% Of renal
failure
WT 10 0 0
HIV-Tg+vehicle 0 10 100a
HIV-Tg+roflumilast 6 4 40
HIV-Tg+Am580 7 3 30
HIV-Tg+roflumilast+Am580 10 0 0b
Abbreviations: BUN, blood urea nitrogen; HIV, human immunodeficiency virus;
Tg, transgenic; WT, wild type.
The percentage of mice that developed renal failure in each group was determined.
Renal failure was defined by elevation of BUN that is more than 2 s.d.s above the
mean BUN in the WT group (BUN430mg/dl). Paired w2-analysis was used to
calculate the difference between the groups.
aPo0.05 for HIV-Tg+vehicle vs. all other groups.
bPo0.05 for HIV-Tg+roflumilast+Am580 vs. HIV-Tg+roflumilast, and HIV-Tg+roflu-
milast+Am580 vs. HIV-Tg+Am580, n=10.
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and protected podocytes from injury in HIV-Tg mice
compared with mice treated with roflumilast or Am580
alone. These findings indicate that PDE4 inhibitors and
RARa agonists could be used in combination to treat patients
with kidney disease.
Retinoids exert their effects by binding two families of
nuclear receptors, the RARs and the retinoid X receptors. The
RARs and retinoid X receptors are expressed in a variety of
tissues including the kidney.11 They affect gene transcription
either directly by binding to the retinoic acid-response
elements of a promoter region21 or indirectly by modulating
transcription factors or intracellular signaling pathways.22,23
It has been shown that ATRA-induced gene expression is
mostly independent of retinoic acid-response elements.21,24
HIV-Tg
HIV-Tg+vehicle
HIV-Tg+Rof+Am580
×2000 ×5000
WT Vehicle Am580 Rof Rof+Am580
Figure 3 |Kidney histology. (a) Human immunodeficiency virus (HIV)-transgenic (Tg) mice were treated with vehicle, Am580,
roflumilast (Rof), or RofþAm580 from the age of 4 weeks to 9 weeks. Hematoxylin and eosin staining of kidney sections was performed
at the end of the study. HIV-Tgþ vehicle had severe glomerulosclerosis, tubular microcysts and casts. These pathological changes were
less frequently observed in mice treated with Am580, Rof, or RofþAm580. Some mice treated with Rof or Am580 alone developed
mild glomerulosclerosis and tubular casts. (b) Electron microscopy shows a significant improvement of foot process effacement in
HIV-Tgþ RofþAm580 compared with HIV-Tgþ vehicle. Representative pictures are shown here.
Table 2 | Effects of Am580 and roflumilast on kidney histology
CG index Podocyte hypertrophy Tubular casts/cysts
HIV-Tg+vehicle 15.6±6.2 1.5±0.9 10.4±4.2
HIV-Tg+Am580 3.6±2.3a 0.5±0.5a 2.8±3.3a
HIV-Tg+roflumilast 4.6±3.0a 0.7±0.6a 3.8±3.2a
HIV-Tg+Am580+roflumilast 1.6±0.8b 0b 0b
Abbreviations: CG, collapsing glomerulosclerosis; HIV, human immunodeficiency virus; Tg, transgenic.
HIV-Tg mice were treated with Am580 or roflumilast alone or in combination for 5 weeks as compared to the mice treated with vehicle. Kidney histology of these mice was
analyzed as described in Materials and Methods, n=10. We performed nonparametric Mann–Whitney test between pairs and found the following:
aPo0.05 when we compared HIV-Tg mice treated with either Am580 or roflumilast alone to the mice treated with vehicle and
bPo0.05 when we compared HIV-Tg mice treated with both drugs to the mice treated with Am580 or roflumilast alone.
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Several studies indicate that ATRA induces leukemia cell
differentiation through the activation of intracellular signal-
ing pathways.25,26 Consistent with our findings in podocytes,
ATRA can induce rapid cAMP production and increase PKA
activity in acute myeloblastic leukemia cells to induce
leukemia cell differentiation.9 A synergistic effect between
ATRA and an inhibitor of phosphodiesterase has also been
observed for myeloid differentiation.15
Consistent with our findings, ATRA has been previously
shown to induce neurite outgrowth in PC12 cells through
CREB phosphorylation, which is independent of the retinoic
acid-response elements.27 CREB is phosphorylated by several
signaling pathways including PKA and mitogen-activated
protein kinase1,2, which could be activated by ATRA.28
CREB is a key transcription factor for neuronal differentia-
tion. Our previous in vitro studies suggest that CREB has an
important role in podocyte differentiation.12,17 Here, our
data indicate that CREB may also mediate the renal
protective effects of ATRA in vivo.
Our studies suggest that PDE4 inhibitor enhances the
effects of RARa agonist by increasing intracellular cAMP
concentration. Components of the cAMP signaling pathway
exist within the podocyte.29,30 Consistent with our findings,
activation of the cAMP–PKA pathway in podocytes is known
to influences cell morphology, actin assembly, and matrix
production.30 In addition, cAMP seems to attenuate the
detrimental effects of hormones that activate the Ca2þ /
protein kinase C pathway.30 Overall, the cAMP pathway
seems to exert a protective effect on podocytes survival.
The clinical use of retinoids in patients with kidney disease
is limited by its significant side effects. Our studies suggest
that adding a PDE4 inhibitor to a RARa agonist provides
additional renal protection. In the future, we could test to see
whether using PDE4 inhibitors in combination with a lower
dose of RA or RARa agonist would offer the same renal
protection while eschewing the side effects associated with
high-dose RA and RARa agonists. Food and Drug Admin-
istartion recently approved roflumilast for the treatment of
asthma and chronic obstructive pulmonary disease. Its side
effects are relatively minor. Therefore, we speculate that the
combination of RARa agonist and roflumilast could be a
potential new therapy regimen for patients with glomerular
disease such as HIVAN.
HIV-Tg mouse is the best mouse model to study HIVAN
because it mimics human kidney disease.31 However, it is
known that the severity of kidney disease in HIV-Tg mice
varies among the different colonies, which is likely due to
different genetic penetrance. HIV-1 transgenic mice (Tg26)
originally reported by Kopp et al.32 developed renal disease
that is less severe with a later onset. HIV-Tg mice used in the
current studies were derived from a Tg26 mouse with severe
kidney disease. These mice developed proteinuria at the age
of 4 weeks and mild-to-moderate renal insufficiency at the
age of 8–10 weeks. The severity of disease in HIV-Tg mice
more closely mimics human HIVAN. It is also interesting that
RARa agonist and roflumilast improve kidney disease
without affecting the expression of HIV genes. These findings
suggest that these two drugs protect kidney cells against
injury likely through affecting the host response of the kidney
cells to the HIV gene expression.
Even though our data indicate that this new therapy
regime is effective in a murine model of HIVAN, previous
studies have shown that RA is effective in animal models of
other non-HIVAN kidney diseases.11 We believe this new
therapeutic combination could be applied to the treatment of
other kidney glomerular diseases caused by podocyte injury.
Our unpublished data indicate that Am580 may also improve
kidney disease in a murine model of diabetic nephropathy.
In summary, the combination of a PDE4 inhibitor with a
RARa agonist provides renal protection in HIV-Tg mice by
activating the cAMP/PKA/CREB pathway. These new find-
ings provide a scientific basis to design a therapeutic regimen
that could be used for patients with glomerular diseases
including HIVAN.
MATERIALS AND METHODS
Animal studies
It is known that HIV-Tg mice from different colonies have variable
severity of kidney phenotype. In this rederived colony, about 80%
mice develop more than 1þ proteinuria at the age of 4 weeks, based
on urine dipstick, and mild-to-moderate renal insufficiency at age of
8–10 weeks. These mice also developed cataract, skin papillomas,
and mild edema by the age of 8–10 weeks. For the current studies,
we pre-screened the HIV-Tg mice by using urine dipstick, and mice
with 1þ to 2þ of proteinuria at the age of 4 weeks were selected
for the studies (10 mice were selected, 3 mice had 1þ and 7 mice
had 2þ proteinuria by urine dipstick) and the age-matched
littermates were used as the control. As both male and female
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Figure 4 |Real-time polymerase chain reaction (PCR) analysis
of podocyte differentiation (a) and proliferation (b) markers.
Glomeruli were isolated from these mice treated with vehicle,
Am580, roflumilast (Rof), or RofþAm580 for 5 weeks. Total RNA
was isolated from the glomeruli for real-time PCR analysis of
podocyte differentiation markers (synaptopodin, nephrin, and
wild type (WT-1)), proliferation markers (Ki67 and cyclin E), and
HIV nef. The ratio of these genes to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is presented (n¼ 10). Analysis of
variance followed by pairwise analysis with Bonferroni correction
identified a significant difference between vehicle vs. Am580
(*Po0.01), vehicle vs. Rof (*Po0.01), RofþAm580 vs. Rof
(**Po0.01), and RofþAm580 vs. Am580 (**Po0.01). HIV, human
immunodeficiency virus.
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HIV-Tg mice develop kidney disease similarly, we decided to use five
male and five female in each group (n¼ 10). Mice were fed with the
vehicle (1.3% polyethylene glycol 400; 4% methylcellulose solution),
roflumilast (5mg/kg/day; purchased from LGM Pharma, Boca
Raton, FL), Am580 (0.3mg/kg/day; supplied by Dr K Shudo at
Research Foundation ITSUU Laboratory, Molecular and Functional
Bioscience, Tokyo, Japan), or both Am580 and roflumilast for a total
of 5 weeks. Roflumilast was dissolved in the vehicle and given as
daily gavage and Am580 was mixed in the animal chow. Unrestricted
food and water were provided throughout the duration of the
experiment. Body weight was recorded every week. Urine samples
were collected weekly for determination of albuminruia and
creatinine ratio. After 5 weeks of treatment, mice were euthanized
at 9 weeks of age for blood, urine, and tissue collection. BUN, a
marker of glomerular function, was measured. Kidneys were
collected and kidney weight was recorded. A section of the kidney
was fixed in formalin. Glomeruli were isolated and total RNA
extracted from the glomeruli for determination of gene expression
by real-time PCR. Western blot was performed for phosphorylation
of CREB. All animal studies were performed according to the
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Figure 5 | Effects of Am580 and/or roflumilast on the expression of podocyte proliferation and differentiation markers in
HIV-Tg mice. (a) Immunofluorescent staining of podocyte differentiation markers. Kidney sections from these mice were used for
immunostaining of podocyte differentiation and proliferation markers as described in Materials and Methods. 4,6-Diamidino-2-phenylindole
staining was used to mark the nucleus. Representative pictures of five mice in each group are shown (original magnification  400). As
glomeruli with collapsing glomerulosclerosis are in the minority, selected pictures of non-sclerotic glomeruli, which are more representative
of the overall histological findings, are shown. (b) Western blot analysis of cyclin E: glomerular lysates from these mice was used for western
blot analysis of cyclin E. The representative blots of two mice in each group were shown. Each lane represents one mouse. (c) We performed
western blot analysis for a total of six mice in each group and the average density of cyclin E and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in these mice was analyzed by densitometry. The ratio of cyclin E/GAPDH relative to vehicle-treated mice is shown.
*Po0.05: HIV-Tgþ vehicle vs. HIV-Tgþ Rof and HIV-Tgþ vehicle vs. HIV-TgþAm580. **Po0.05: HIV-TgþAm580 vs.
HIV-Tgþ RofþAm580 and HIV-Tgþ Rof vs. HIV-Tgþ RofþAm580; n¼ 6. HIV, human immunodeficiency virus; Tg, transgenic.
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protocols approved by the Institutional Animal Care and Use
Committee at the Mount Sinai School of Medicine.
Measurement of BUN, urine protein, and creatinine
BUN was measured using a commercially available assay
(Bioassay Systems, Hayward, CA). Urine albumin was quantified
by ELISA (Bethyl Laboratory, Houston, TX). Urine creatinine was
measured in the same samples using the QuantiChrom Creatinine
Assay Kit (DICT-500, Bioassay Systems) following manufacturer’s
protocol. Urine albumin excretion is expressed as the ratio of
albumin to creatinine.
Quantitative histopathology
Mice were perfused with phosphate-buffered saline containing 4%
paraformaldehyde and kidneys were further fixed in 4% paraform-
aldehyde for 2 h. Kidney tissue was embedded into paraffin by
American Histolabs (Gaithersberg, MD). Kidney histology was
examined after periodic acid–Schiff staining. Glomerulosclerosis
was scored as described previously by Dr D’Agati.33 Briefly, each
specimen received a score for three parameters: percentage of
collapsing glomerular sclerosis, percentage of tubular cysts or casts,
and podocyte hypertrophy. The percentage of collapsing glomerulo-
sclerosis was obtained by identifying the total number of glomeruli
with collapse and segmental or global sclerosis and dividing this
number by the total number of glomeruli seen. The percentage of
tubular cysts or casts score was obtained by the number of tubules
with either microcystic dilatation or filled with casts divided by the
total number of tubular cross-sections in a representative area.
Finally, the degree of podocyte hypertrophy was scored as 0 (absent),
1þ (podocyte hypertrophy observed in o25% of all glomeruli),
2þ (podocyte hypertrophy observed in between 25 and 50% of all
glomeruli), and 3þ (podocyte hypertrophy in 450% of all
glomeruli). The podocyte hypertrophy is evaluated based on the
morphology under light microscopy as described previously.33
Electronic microscopy
Mice were perfused with phosphate-buffered saline and then
immediately fixed in glutaraldehyde for electron microscopy study
performed at the histopathology core facility of the Mount Sinai
School of Medicine.
Isolation of glomeruli from mice for western blot and
real-time PCR
Glomeruli were isolated as described.34 Briefly, animals were
perfused with 60ml of Hank’s buffered salt solution containing
2.5mg/ml iron oxide and 1% bovine serum albumin. After per-
fusion, kidneys were removed, decapsulated, minced into 1-mm3
pieces, and digested in Hank’s buffered salt solution containing
WT Vehicle
Vehicle
T-CREB
Am580
Am580
Rof
Rof
Rof+Am580
-Green: Nestin
Rof+Am580
7
6
5
4
3
2
1
0
*
*
**
HIV-Tg
Ve
hic
le
Ro
f
Am
58
0
Am
58
0+
Ro
f
HIV-Tg
p-CREB
-Pink: p-CREB
p-
CR
EB
/T
-C
RE
B 
ra
tio
Figure 6 |Glomerular cAMP-responsive element binding protein (CREB) phosphorylation. Glomeruli were isolated from these mice
treated with vehicle, Am580 or roflumilast (Rof) alone or in combination for 5 weeks. Nuclear lysates were obtained from glomeruli of these
mice for western blot analysis for phosphor- (p-CREB) and total CREB (T-CREB). (a) Representative blots of two mice in each group. We
performed western blot analysis for a total of six mice in each group. The average density of p-CREB and T-CREB in these mice was analyzed
by the densitometry. (b) The ratio of p-CREB to T-CREB was calculated and the ratio of p-CREB/T-CREB related to the mice treated with
vehicle, n¼ 6, *Po0.01 for vehicle vs. Rof and vehicle vs. Am580, **Po0.01 for Am580 vs. RofþAm580 and or Rof vs. RofþAm580.
Immunoflorescent staining for p-CREB was performed in kidney sections from six mice per group and the representative pictures are
shown in c. The green color indicates nestin and the pink color indicates the colocalization of p-CREB and 4,6-diamidino-2-phenylindole
(original magnification  400). HIV, human immunodeficiency virus; Tg, transgenic; WT, wild type.
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1mg/ml collagenase A and 100U/ml deoxyribonuclease I. Digested
tissue was passed through a 100-micron cell strainer and collected
by centrifugation. The pellet was resuspended in 2ml of Hank’s
buffered salt solution and glomeruli were collected using a magnet.
The purity of glomerular was verified under microscopy and by
western blot analysis for podocyte-specific markers, including
synaptopodin, nephrin, and WT-1.
Real-time PCR
Total RNA was isolated from glomeruli using TRIzol (Life
Technologies, Grand Island, NY). Extracted RNA samples were
reverse transcribed to complimentary DNA using SuperScript III
First-Strand Synthesis System (Life Technologies) for RT-PCR. Real-
time PCR was performed on complimentary DNA samples using
Quantitect SYBR Green PCR Kit (Qiagen, Valencia, CA) in a Roche
Lightcycler (Roche Applied Science, Indianapolis, IN). Primers used
for synaptopodin, nephrin, WT-1, cyclin E, and Ki67 were the same
as described.16 Data were normalized to housekeeping genes
(GAPDH) and presented as fold increase compared with compli-
mentary DNA from WT animals using the 2DDCt method.
Western blot
Glomeruli are lysed with a buffer containing 1% NP40, a protease
inhibitor cocktail and tyrosine and serine-threonine phosphor-
ylation inhibitors. After determination of protein concentration,
glomerular lysates were subjected to western blot analysis
using the following specific antibodies: anti-phospho CREB anti-
body from Cell Signaling Technology (Danvers, MA) and anti-total
CREB from Millipore (Billerica, MA). Anti-cylcin E antibody was
from Santa Cruz Biotechnology, Santa Cruz, CA, and anti-GAPDH
antibody was from Sigma (St Louis, MO). Densitometric analysis of
western blot results was quantified using ImageJ (National Institutes
of Health, Bethesda, MD, http://imagej.nih.gov/ij/, 1997–2011).
Immunofluorescence
Paraffin-embedded sections were deparaffinized prior to incubation
with primary antibodies for 1 h at room temperature. Fluorescent-
labeled second antibodies with different wavelengths were used for
colocalization study. Sections were examined by epifluorescent
microscopy. Antibodies used for immunostaining are anti-nephrin
antibody (a gift from Dr Larry Holzeman), anti-synaptopodin
(Fitzgerald Industries International, Acton, MA), anti-WT1 and
anti-nestin (Santa Cruz Biotechnology), and anti-phosphor-CREB
(Cell Signaling Technology), and anti-Ki67 (Vector Laboratories,
Burlingame, CA).
Statistical analysis
Data were expressed as mean±standard deviation (X±s.d.). The
unpaired T-test was used to analyze data between two groups.
Analysis of variance was used for multiple group analysis, and the
comparison between the groups was further analyzed using
Bonferroni correction. The renal scoring data were analyzed by
using nonparametric Wilcoxon signed rank test. The percentage of
mice in each group did or did not develop renal disease was
summarized in a contingency table and analyzed by w2-test.
Statistical significance will be considered when Po0.05.
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